Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab, Nivolumab, and Ciforadenant in First-line Advanced Renal Cell Carcinoma
NCT05501054Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ciforadenant in renal cell carcinoma (RCC), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2023; status: active, not recruiting.
02
Drugs
ciforadenant
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT05501054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501054.